Study of a new therapy targeting proteins of high-risk HPV

• Project/Area Number: 24791719
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Obstetrics and gynecology
• Research Institution: Keio University
• Principal Investigator: OHNO Akiko 慶應義塾大学, 医学部, 共同研究員 (70383883)
• Project Period (FY): 2012-04-01 – 2014-03-31
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000); Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: HPV

Research Abstract

Adenovirus vector expressing IgG signal peptide(ss)-cell penetrating peptide(Atp)-E7 pRb-binding peptide(RbB)-E7 c-myc-binding peptide(MycB)-pentameric COMP domain peptide(COMP)-6xHis was constructed. Several deletion variants as well as vector containing partial HPV E6 peptide were also generated. Cell lines such as HeLa, CaSki, C33a, and A431 were infected with these adenoviruses to examine the cytotoxicity. Growth inhibition was observed only in HPV18 positive HeLa.